A new initiative from the American Heart Association (AHA) aims to educate and engage pharmacists in caring for patients with AFib.

A study of more than 11,000 U.S. adults suggests an association between acid-suppression therapy, including PPIs, H2RAs, and generic antacids, and an increased risk of migraine and severe headaches compared with people who do not take these medications. The risk was 70% higher for those using PPIs, 40% higher for those taking H2RAs, and 30% higher for generic antacids.

Authors of a research letter in JAMA Cardiology report that declines in heart failure–related mortality from 1999 to 2012 have been entirely undone by reversals from 2012 to 2021.

Clinicians continue to treat resistant gram-negative infections with older, generic antibiotics that are considered to be less effective and less safe, even though FDA has approved seven next-generation gram-negative antibiotics between 2014 and 2019.

States have adopted their own laws to regulate PBMs, according to a new report from the U.S Government Accountability Office (GAO).